GERN
Price
$1.35
Change
-$0.11 (-7.48%)
Updated
Apr 4, 03:47 PM (EDT)
Capitalization
1.01B
38 days until earnings call
PULM
Price
$5.30
Change
-$0.66 (-11.07%)
Updated
Apr 4, 03:44 PM (EDT)
Capitalization
21.77M
35 days until earnings call
Ad is loading...

GERN vs PULM

Header iconGERN vs PULM Comparison
Open Charts GERN vs PULMBanner chart's image
Geron
Price$1.35
Change-$0.11 (-7.48%)
Volume$52.5K
Capitalization1.01B
Pulmatrix
Price$5.30
Change-$0.66 (-11.07%)
Volume$300
Capitalization21.77M
GERN vs PULM Comparison Chart
Loading...
GERN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
PULM
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
GERN vs. PULM commentary
Apr 04, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is GERN is a Hold and PULM is a Hold.

Ad is loading...
COMPARISON
Comparison
Apr 04, 2025
Stock price -- (GERN: $1.47 vs. PULM: $5.96)
Brand notoriety: GERN and PULM are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: GERN: 62% vs. PULM: 57%
Market capitalization -- GERN: $1.01B vs. PULM: $21.77M
GERN [@Biotechnology] is valued at $1.01B. PULM’s [@Biotechnology] market capitalization is $21.77M. The market cap for tickers in the [@Biotechnology] industry ranges from $299.64B to $0. The average market capitalization across the [@Biotechnology] industry is $2.17B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

GERN’s FA Score shows that 0 FA rating(s) are green whilePULM’s FA Score has 0 green FA rating(s).

  • GERN’s FA Score: 0 green, 5 red.
  • PULM’s FA Score: 0 green, 5 red.
According to our system of comparison, PULM is a better buy in the long-term than GERN.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

GERN’s TA Score shows that 5 TA indicator(s) are bullish while PULM’s TA Score has 2 bullish TA indicator(s).

  • GERN’s TA Score: 5 bullish, 3 bearish.
  • PULM’s TA Score: 2 bullish, 6 bearish.
According to our system of comparison, GERN is a better buy in the short-term than PULM.

Price Growth

GERN (@Biotechnology) experienced а -10.91% price change this week, while PULM (@Biotechnology) price change was -17.45% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -11.26%. For the same industry, the average monthly price growth was -17.11%, and the average quarterly price growth was -18.89%.

Reported Earning Dates

GERN is expected to report earnings on May 12, 2025.

PULM is expected to report earnings on May 09, 2025.

Industries' Descriptions

@Biotechnology (-11.26% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
GERN($1.01B) has a higher market cap than PULM($21.8M). PULM YTD gains are higher at: -14.613 vs. GERN (-58.475). PULM has higher annual earnings (EBITDA): -6.78M vs. GERN (-154.85M). GERN has more cash in the bank: 407M vs. PULM (10.8M). PULM has less debt than GERN: PULM (0) vs GERN (122M). GERN has higher revenues than PULM: GERN (77M) vs PULM (10M).
GERNPULMGERN / PULM
Capitalization1.01B21.8M4,647%
EBITDA-154.85M-6.78M2,286%
Gain YTD-58.475-14.613400%
P/E RatioN/AN/A-
Revenue77M10M770%
Total Cash407M10.8M3,769%
Total Debt122M0-
FUNDAMENTALS RATINGS
GERN vs PULM: Fundamental Ratings
GERN
PULM
OUTLOOK RATING
1..100
7253
VALUATION
overvalued / fair valued / undervalued
1..100
92
Overvalued
40
Fair valued
PROFIT vs RISK RATING
1..100
84100
SMR RATING
1..100
9898
PRICE GROWTH RATING
1..100
9235
P/E GROWTH RATING
1..100
66100
SEASONALITY SCORE
1..100
n/an/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

PULM's Valuation (40) in the Biotechnology industry is somewhat better than the same rating for GERN (92). This means that PULM’s stock grew somewhat faster than GERN’s over the last 12 months.

GERN's Profit vs Risk Rating (84) in the Biotechnology industry is in the same range as PULM (100). This means that GERN’s stock grew similarly to PULM’s over the last 12 months.

GERN's SMR Rating (98) in the Biotechnology industry is in the same range as PULM (98). This means that GERN’s stock grew similarly to PULM’s over the last 12 months.

PULM's Price Growth Rating (35) in the Biotechnology industry is somewhat better than the same rating for GERN (92). This means that PULM’s stock grew somewhat faster than GERN’s over the last 12 months.

GERN's P/E Growth Rating (66) in the Biotechnology industry is somewhat better than the same rating for PULM (100). This means that GERN’s stock grew somewhat faster than PULM’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
GERNPULM
RSI
ODDS (%)
Bullish Trend 2 days ago
70%
N/A
Stochastic
ODDS (%)
Bullish Trend 2 days ago
76%
Bullish Trend 2 days ago
77%
Momentum
ODDS (%)
Bearish Trend 2 days ago
78%
Bearish Trend 2 days ago
90%
MACD
ODDS (%)
Bullish Trend 2 days ago
80%
Bearish Trend 2 days ago
87%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
80%
Bearish Trend 2 days ago
85%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
81%
Bearish Trend 2 days ago
86%
Advances
ODDS (%)
Bullish Trend 15 days ago
76%
Bullish Trend 22 days ago
71%
Declines
ODDS (%)
Bearish Trend 4 days ago
75%
Bearish Trend 2 days ago
86%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
79%
N/A
Aroon
ODDS (%)
Bearish Trend 2 days ago
77%
Bearish Trend 2 days ago
90%
View a ticker or compare two or three
Ad is loading...
GERN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
PULM
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
LLYVK66.56-4.98
-6.96%
Liberty Media Corp
TROW86.22-7.68
-8.18%
T Rowe Price Group
LITM0.46-0.06
-10.84%
Snow Lake Resources Ltd
RMBL2.40-0.38
-13.67%
RumbleOn
SCVL19.24-3.76
-16.35%
Shoe Carnival